M. Cheever

Pulmonary and Respiratory Medicine · 2009–2016

A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom M. Cheever trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. E. Small
  2. Celestia S. Higano

Papers from M. Cheever's perspective

Ordered by how strongly the researchers M. Cheever trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
  2. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. (Journal of Clinical Oncology)
  3. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer (Cancer)
  4. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. (Journal of Clinical Oncology)
  5. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (New England Journal of Medicine)
  6. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (New England Journal of Medicine)
  7. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. (Journal of Clinical Oncology)
  8. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. (American Journal of Pathology)
  9. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. (Cancer Research)
  10. Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. (Journal of Urology)

Their papers